Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting


Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

TUSTIN, CA -- (Marketwire) -- 04/01/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 104th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 6-10, 2013 in Washington, DC. Data to be presented include studies investigating the immune stimulating mechanism of action of Peregrine's lead phosphatidylserine (PS)-targeting oncology clinical candidate bavituximab and the anti-tumor and imaging potential of other PS-targeting constructs.

Abstract Details:

Abstract Number 1244 Presentation Title: Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice Presentation Time: Monday, Apr 08, 2013, 1:00 PM - 5:00 PM EDT Location: Hall A-C, Poster Section 5 Poster Board Number: 24 Author Block: Yi Yin, Xianming Huang, Dan Ye, Philip Thorpe. UT Southwestern Medical Ctr., Dallas, TX

Abstract Number 2850 Presentation Title: Predicting anti-tumor responses to phosphatidylserine targeting antibodies using tumor imaging Presentation Time: Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM EDT Location: Hall A-C, Poster Section 21 Poster Board Number: 22

Author Block: Jian Gong(1), Richard Archer(1), Van Nguyen(1), Christopher C.W. Hughes(2), Jeff Hutchins(1), Bruce Freimark(1). 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. University of California, Irvine, Irvine, CA

Abstract Number: 4326 Presentation Title: Phosphatidylserine-targeting 'betabodies' for the treatment of cancer Presentation Time: Tuesday, Apr 09, 2013, 1:00 PM - 5:00 PM EDT Location: Hall A-C, Poster Section 36 Poster Board Number: 9

Author Block: Xianming Huang(1), Dan Ye(1), Troy Luster(2), E. Sally Ward(1), Philip Thorpe(1). 1. UT Southwestern Medical Ctr., Dallas, TX; 2. Human Genome Science, Maryland, MD

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical tr ials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact: Christopher Keenan or Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 info@peregrineinc.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement